Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04256980 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 5, 2020
Last Update Posted : October 4, 2022
|
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Information provided by (Responsible Party):
Innovent Biologics (Suzhou) Co. Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | June 27, 2022 |
| Estimated Study Completion Date : | December 30, 2023 |